首页 > 最新文献

American journal of therapeutics最新文献

英文 中文
Risk Analysis of Air Embolism in Intraosseous Infusions Versus Peripheral and Central Venous Access in Septic Shock Patient. 脓毒症休克患者使用鞘内输液与外周静脉和中心静脉通路时发生空气栓塞的风险分析
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-09 DOI: 10.1097/MJT.0000000000001776
Rui Huo, Kunqiang Liu, Xiaohong Pu, Shuquan Tang
{"title":"Risk Analysis of Air Embolism in Intraosseous Infusions Versus Peripheral and Central Venous Access in Septic Shock Patient.","authors":"Rui Huo, Kunqiang Liu, Xiaohong Pu, Shuquan Tang","doi":"10.1097/MJT.0000000000001776","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001776","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guanfacine Used With Antipsychotics May Cause Bradycardia to Become Apparent After Discontinuation of Antipsychotics. 关法辛与抗精神病药物合用可能导致停用抗精神病药物后出现心动过缓。
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-01 Epub Date: 2024-01-18 DOI: 10.1097/MJT.0000000000001654
Tsukasa Murata, Katsuaki Uno, Takahiko Nagamine
{"title":"Guanfacine Used With Antipsychotics May Cause Bradycardia to Become Apparent After Discontinuation of Antipsychotics.","authors":"Tsukasa Murata, Katsuaki Uno, Takahiko Nagamine","doi":"10.1097/MJT.0000000000001654","DOIUrl":"10.1097/MJT.0000000000001654","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139501804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atezolizumab-Associated Retiform Purpura. 阿特珠单抗相关视网膜紫癜
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-01 Epub Date: 2024-02-09 DOI: 10.1097/MJT.0000000000001665
Sabeen Sidiki, Rawish Fatima, Nahimarys Colón Hernández, Nezam Altorok
{"title":"Atezolizumab-Associated Retiform Purpura.","authors":"Sabeen Sidiki, Rawish Fatima, Nahimarys Colón Hernández, Nezam Altorok","doi":"10.1097/MJT.0000000000001665","DOIUrl":"10.1097/MJT.0000000000001665","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139711256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Secukinumab-Induced Bullous Pemphigoid in a Patient With Psoriatic Arthritis. 一名银屑病关节炎患者因塞库单抗诱发大疱性类天疱疮
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-01 Epub Date: 2023-06-07 DOI: 10.1097/MJT.0000000000001642
Rawish Fatima, Nezam Altorok
{"title":"Secukinumab-Induced Bullous Pemphigoid in a Patient With Psoriatic Arthritis.","authors":"Rawish Fatima, Nezam Altorok","doi":"10.1097/MJT.0000000000001642","DOIUrl":"10.1097/MJT.0000000000001642","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9595775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of Adverse Events Using Flumazenil in Patients With Iatrogenic Benzodiazepine Delirium: A Retrospective Study. 使用氟马西尼治疗苯二氮卓类药物所致谵妄患者的不良事件发生率:回顾性研究。
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-01 DOI: 10.1097/MJT.0000000000001686
Michelle A Hieger, Philip W Moore, Kevin F Maskell

Background: Flumazenil is a competitive benzodiazepine (BZD) antagonist most used for treating delirium in BZD overdoses. Since its introduction, many have expressed concerns about its safety secondary to the risk of inducing BZD withdrawal and refractory seizures.

Study question: What is the incidence of adverse drug events after the administration of flumazenil in patients with suspected iatrogenic BZD delirium?

Study design: This is a retrospective cross-sectional study of patients from a single center from 2010 to 2013. Patients experiencing delirium after receiving BZDs in the hospital were included if they had a bedside toxicology consult and were administered flumazenil. Patients were excluded if they were given BZDs for ethanol withdrawal or if they did not have mental status documentation before and after flumazenil administration. Descriptive statistics were calculated.

Measures and outcomes: The primary outcome was the incidence of adverse drug events after flumazenil administration. The secondary outcome was the efficacy of flumazenil determined by the patient's mental status.

Results: A total of 501 patient records were reviewed, and 206 patients were included in the final analysis. Of those patients, 172 (83.5%) experienced an objective improvement in their mental status within 1 hour after flumazenil administration. A total of 5 patients experienced adverse events (2.4%), 95% confidence interval (0.78, 5.54). Of these, 3 patients experienced minor agitation or restlessness without pharmacologic intervention. Two patients experienced moderate agitation or restlessness that resolved with haloperidol or physostigmine administration. No patients had a reported seizure, 95% confidence interval (0.0, 1.77).

Conclusions: Flumazenil seems to be a safe and effective intervention for the reversal of delirium secondary to iatrogenic BZD administration.

背景:氟马西尼是一种竞争性苯并二氮卓(BZD)拮抗剂,最常用于治疗BZD过量引起的谵妄。自问世以来,许多人对其安全性表示担忧,因为它有诱发 BZD 戒断和难治性癫痫发作的风险:研究问题:对疑似先天性 BZD 谵妄的患者使用氟马西尼后,药物不良事件的发生率如何?这是一项回顾性横断面研究,研究对象为 2010 年至 2013 年期间来自一个中心的患者。在医院接受 BZDs 治疗后出现谵妄的患者,如果进行了床旁毒理学会诊并服用了氟马西尼,则纳入研究对象。如果患者因乙醇戒断而服用了BZDs,或在服用氟马西尼前后没有精神状态记录,则排除在外。计算了描述性统计:主要结果是服用氟马西尼后药物不良反应的发生率。次要结果是根据患者的精神状态判断氟马西尼的疗效:共审查了 501 份病历,206 名患者被纳入最终分析。在这些患者中,有 172 人(83.5%)在服用氟马西尼后 1 小时内精神状态得到客观改善。共有 5 名患者出现不良反应(2.4%),95% 置信区间(0.78, 5.54)。其中,3 名患者在没有药物干预的情况下出现了轻微的躁动或不安。两名患者出现了中度躁动或不安,但在服用氟哌啶醇或波司的明后症状得到缓解。没有患者出现癫痫发作,95% 置信区间为 (0.0, 1.77):氟马西尼似乎是一种安全有效的干预措施,可逆转因先天性服用 BZD 而导致的谵妄。
{"title":"Incidence of Adverse Events Using Flumazenil in Patients With Iatrogenic Benzodiazepine Delirium: A Retrospective Study.","authors":"Michelle A Hieger, Philip W Moore, Kevin F Maskell","doi":"10.1097/MJT.0000000000001686","DOIUrl":"10.1097/MJT.0000000000001686","url":null,"abstract":"<p><strong>Background: </strong>Flumazenil is a competitive benzodiazepine (BZD) antagonist most used for treating delirium in BZD overdoses. Since its introduction, many have expressed concerns about its safety secondary to the risk of inducing BZD withdrawal and refractory seizures.</p><p><strong>Study question: </strong>What is the incidence of adverse drug events after the administration of flumazenil in patients with suspected iatrogenic BZD delirium?</p><p><strong>Study design: </strong>This is a retrospective cross-sectional study of patients from a single center from 2010 to 2013. Patients experiencing delirium after receiving BZDs in the hospital were included if they had a bedside toxicology consult and were administered flumazenil. Patients were excluded if they were given BZDs for ethanol withdrawal or if they did not have mental status documentation before and after flumazenil administration. Descriptive statistics were calculated.</p><p><strong>Measures and outcomes: </strong>The primary outcome was the incidence of adverse drug events after flumazenil administration. The secondary outcome was the efficacy of flumazenil determined by the patient's mental status.</p><p><strong>Results: </strong>A total of 501 patient records were reviewed, and 206 patients were included in the final analysis. Of those patients, 172 (83.5%) experienced an objective improvement in their mental status within 1 hour after flumazenil administration. A total of 5 patients experienced adverse events (2.4%), 95% confidence interval (0.78, 5.54). Of these, 3 patients experienced minor agitation or restlessness without pharmacologic intervention. Two patients experienced moderate agitation or restlessness that resolved with haloperidol or physostigmine administration. No patients had a reported seizure, 95% confidence interval (0.0, 1.77).</p><p><strong>Conclusions: </strong>Flumazenil seems to be a safe and effective intervention for the reversal of delirium secondary to iatrogenic BZD administration.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141557853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Favipiravir for the Treatment of Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 法维拉韦治疗 COVID-19 住院患者:随机对照试验的系统回顾和元分析》。
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-01 Epub Date: 2024-01-23 DOI: 10.1097/MJT.0000000000001688
Aiman Naveed, Huzaifa Ahmad Cheema, Abia Shahid, Mohammad Umer, Hassan Ul Hussain, Mohammad Ebad Ur Rehman, Harpreet Singh, Jonathan S Kurman, Syeda Sahra, Faran Ahmad, Sharjeel Ahmad, Sana Iqbal
{"title":"Favipiravir for the Treatment of Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Aiman Naveed, Huzaifa Ahmad Cheema, Abia Shahid, Mohammad Umer, Hassan Ul Hussain, Mohammad Ebad Ur Rehman, Harpreet Singh, Jonathan S Kurman, Syeda Sahra, Faran Ahmad, Sharjeel Ahmad, Sana Iqbal","doi":"10.1097/MJT.0000000000001688","DOIUrl":"10.1097/MJT.0000000000001688","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139519028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAK Inhibitors for Treating Steroid-Dependent IgA Vasculitis. 治疗类固醇依赖性 IgA 血管炎的 JAK 抑制剂
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-01 Epub Date: 2024-03-20 DOI: 10.1097/MJT.0000000000001683
Qingmiao Sun, Juan Bai, Su Wang, Hong Fang, Jianjun Qiao
{"title":"JAK Inhibitors for Treating Steroid-Dependent IgA Vasculitis.","authors":"Qingmiao Sun, Juan Bai, Su Wang, Hong Fang, Jianjun Qiao","doi":"10.1097/MJT.0000000000001683","DOIUrl":"10.1097/MJT.0000000000001683","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lactococcus lactis Strain Plasma for the Treatment of Verruca Plana Juvenilis. 用于治疗幼年疣的乳酸乳球菌菌株血浆。
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-01 DOI: 10.1097/MJT.0000000000001718
Yasuhiro Horiuchi
{"title":"Lactococcus lactis Strain Plasma for the Treatment of Verruca Plana Juvenilis.","authors":"Yasuhiro Horiuchi","doi":"10.1097/MJT.0000000000001718","DOIUrl":"10.1097/MJT.0000000000001718","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141557854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tofacitinib for the Treatment of Trachyonychia. 治疗软骨病的托法替尼
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-01 DOI: 10.1097/MJT.0000000000001676
Xinyue Zhong, Taoming Liu, Linwei Wei, Juan Bai, Hong Fang, Jianjun Qiao
{"title":"Tofacitinib for the Treatment of Trachyonychia.","authors":"Xinyue Zhong, Taoming Liu, Linwei Wei, Juan Bai, Hong Fang, Jianjun Qiao","doi":"10.1097/MJT.0000000000001676","DOIUrl":"10.1097/MJT.0000000000001676","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141557863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lithium Hemodialysis Removal-Related Recurrent Manic Episode in a Bipolar Patient. 一名躁郁症患者因锂离子血液透析去除导致的复发性躁狂发作。
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-01 Epub Date: 2021-04-29 DOI: 10.1097/MJT.0000000000001382
Hung-Yi Lin, Fan-Hsuan Kung, Yueh-Ming Tai, San-Yuan Huang, Yu-Juei Hsu, Nian-Sheng Tzeng
{"title":"Lithium Hemodialysis Removal-Related Recurrent Manic Episode in a Bipolar Patient.","authors":"Hung-Yi Lin, Fan-Hsuan Kung, Yueh-Ming Tai, San-Yuan Huang, Yu-Juei Hsu, Nian-Sheng Tzeng","doi":"10.1097/MJT.0000000000001382","DOIUrl":"10.1097/MJT.0000000000001382","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38999087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American journal of therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1